surufatinib、serplulimab
PreclinicalMonoclonal antibody
surufatinib、serplulimab is one of 4 small molecule programs targeting Advanced Solid Tumors With Neuroendocrine Differentiation. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Advanced Solid Tumors With Neuroendocrine Differentiation
#DrugCompanyPhaseTrials
1Standard Chemotherapy
RochePhase 2
Surufatinib
HHutchison Medipharma Limited
Phase 2
Serplulimab
Shanghai Henlius BiotechPhase 2
surufatinib、serplulimab
SShanghai Changzheng Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for surufatinib、serplulimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Changzheng Hospital